- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06600412
La valutazione del farmaco R3R01 per l'escrezione di proteine nelle urine in pazienti con malattia renale diabetica. (Kidney ABC)
Effetti dell'induttore ABCA1 R3R01 sui livelli di albuminuria nella malattia renale diabetica
The goal of this clinical trial is to to investigate whether the drug R3R01 has a beneficial effect on the amount of protein excreted in the urine in adult patients (above 18 years of age) with type 2 diabetes and resulting kidney disease.
The main questions it aims to answer are:
- Does 3 months of treatment with 200mg of the drug R3R01 morning and evening have a beneficial effect on the amount of protein excreted in the urine in patients with type 2 diabetes and kidney disease?
- Does R3R01 have an effect on kidney function and daily blood pressure?
Researchers will compare the results of 40 people who take R3R01 to 20 people who receive an inactive substance (placebo).
Participants will receive R3R01 or the placebo as an oral tablet and undergo a selection of medical examinations - such as:
- blood samples
- urine tests
- kidney tests involving a radiolabelled marker which is injected into the bloodstream and monitored via blood samples
- 24 hour blood pressure monitoring via a wearable device
- urine pregnancy test (if applicable)
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
An increasing amount of evidence suggests that lipid dysmetabolism and accumulation in the kidneys play a central role in the pathogenesis of kidney disease. This lipotoxicity, in turn, may contribute to the development of albuminuria and chronic kidney disease.
One may surmise that interventions that reduce or prevent the progression of kidney lipid accumulation protect against the progression of kidney disease, including diabetic kidney disease (DKD). Therefore, it is possible inhibiting cholesterol absorption, might effectively protect against lipid accumulation and related disease in the kidneys.
R3R01 is an ATP-binding cassette transporter A1 (ABCA1) inducer, which increases the efflux of cholesterol from the intracellular space in the kidney.
Persons with type 2 diabetes with moderate and severe albuminuria have a poor renal and cardiovascular prognosis. As albuminuria is viewed both as a risk marker but also as a target for intervention, any treatment with antiproteinuric effects could be beneficial. The role of ABCA1 inducer treatment on kidney parameters in diabetic kidney disease is not known. By investigating the impact of ABCA1 inducer treatment on albuminuria, it will be determined whether this intervention may represent a future treatment option.
This study is a single center, double-blind, placebo controlled, parallel group randomized (2:1) study, in 60 people with type 2 diabetes with moderate or severe albuminuria and estimated glomerular filtration rate (eGFR) above 30 ml/min/1.73m2. 40 people will take R3R01 whilst 20 people receive the placebo.
The study's primary objective is to evaluate the effect of 12 weeks treatment with R3R01 on albuminuria in the study population. In addition to a 12 week treatment period, there will be a follow-up period of approximately 24 weeks (168 days). The expected total duration of study participation is up to 36 weeks for each patient.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
Contatti e Sedi
Contatto studio
- Nome: Minh-Nguyêt Duong
- Numero di telefono: +31628443389
- Email: mnduong@narrowrivermgmt.com
Luoghi di studio
-
-
Copenhagen
-
Copenhagen, Copenhagen, Danimarca, 2730
- Reclutamento
- Steno Diabetes Center Copenhagen
-
Contatto:
- Peter Rossing, Professor
- Numero di telefono: +30913383
- Email: Peter.Rossing@regionh.dk
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Adults (above 18 years of age) with controlled type 2 diabetes (hemoglobin A1c less than 10.5%).
- Stable antihypertensive treatment 4 weeks before start of study drug and throughout study duration.
- Titrated to the maximal dose or maximal tolerated dose of renin-angiotensin blocking treatment.
- Stable treatment with lipid lowering agents for at least 4 weeks.
- People on SGLT2-Inhibitors should be on a stable dose of the drug for at least 3 months.
- UACR >30 mg/g and < 5000 mg/g on two consecutive measurements.
- eGFR >30 ml/min/1.73 m2 (CKD-EPIcrea formula).
- Abdominal obesity Women: > 80 cm, Men: > 95 cm or fasting triglyceride >2.0 mmol/l.
- Systolic blood pressure ≥110 mmHg and ≤160 mmHg.
- Both female patients, as well as female partners of male patients who are of child-bearing potential must be willing to not become pregnant for the complete duration of the study and 90 days after the last dose of study medication.
- Males (including sterilized subjects) whose female partners have child-bearing potential, must agree to use male contraception (condoms) during the period from the time of signing the informed consent form through 90 days after the last dose of study drug. They must agree to immediately inform the investigator if their partner becomes pregnant during the study.
Exclusion Criteria:
- Polycystic kidney disease, ANCA-associated vasculitis, or lupus nephritis.
- Ongoing cancer treatment.
- Immunosuppressive therapy or immunosuppression the prior 6 months.
- Nephrotic syndrome.
- Impaired liver function (clinically significant).
- Pregnancy or lactation.
- Failure to understand patient information or to collaborate with the investigator.
- Females of childbearing potential (those who are not surgically sterilized or post-menopausal for at least 1 year) are excluded from participation in the study unless they agree to use highly effective contraception.
- History of hypersensitivity to study drug and/or any of its excipients.
- Hereditary galactose intolerance, total lactase deficiency or glucose-galactose malabsorption.
- Active or planned treatment with a medication that interacts with R3R01.
- Any other medical condition(s) that might put the patient at risk or influence study results in the investigators opinion, or that the investigator deems unsuitable for the study including drug or alcohol abuse or psychiatric, behavioral, or cognitive disorders sufficient to interfere with the patient's ability to understand and comply with the protocol instructions or follow-up procedures.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: R3R01
R3R01 oral tablet (200 mg twice daily) for 12 weeks |
R3R01 is an ATP-binding cassette transporter A1 (ABCA1) inducer, which increases the efflux of cholesterol from the intracellular space in the kidney. Please refer to arm/group description for further information. |
|
Comparatore placebo: Placebo
Placebo oral tablet twice daily for 12 weeks |
Please refer to arm/group description for further information. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Urinary albumin-to-creatinine ratio (UACR)
Lasso di tempo: 12 weeks (84 days)
|
Urinary albumin-to-creatinine ratio (UACR) (Change from baseline to end of treatment at 12 weeks (84 days). |
12 weeks (84 days)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Measured or Estimated Glomerular Filtration Rate
Lasso di tempo: 12 weeks (84 days)
|
Measured glomerular filtration rate (GFR) with plasma clearance of 99Tc-DTPA or eGFR measured with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation based on creatinine and/or cystatin C (change from baseline to end of treatment at 12 weeks (84 days)). |
12 weeks (84 days)
|
|
24 hours ambulatory blood pressure
Lasso di tempo: 12 weeks (84 days)
|
24 hours ambulatory blood pressure (change from baseline to end of treatment at 12 weeks (84 days)). |
12 weeks (84 days)
|
|
Plasma Pharmacokinetics
Lasso di tempo: 24 weeks (168 days)
|
R3R01 plasma concentrations will be measured to determine Maximum plasma concentration (Cmax) |
24 weeks (168 days)
|
|
Plasma Pharmacokinetics
Lasso di tempo: 24 weeks (168 days)
|
R3R01 plasma concentrations will be measured to determine minimum blood plasma concentration (Cmin) |
24 weeks (168 days)
|
|
Plasma Pharmacokinetics
Lasso di tempo: 24 weeks (168 days)
|
R3R01 plasma concentrations will be measured to determine the half-life (T1/2) |
24 weeks (168 days)
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Peter Rossing, dr.med., Steno Diabetes Center Copenhagen
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- R3R01-DKD-201
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .